Targeting of PI3K-a and CDK4/6 kinases in mantle cell lymphomas with dual kinase inhibitor ON 123300-lactate

被引：0
|
作者：
Akula, Balireddy [1 ]
Divakar, Saikrishna A. [2 ]
Bharathi, Vijaya E. [2 ]
Mallireddigari, Muralidhar R. [1 ]
Subbaiah, D. R. C. Venkata [2 ]
Pallela, Venkat R. [1 ]
Billa, Vinay K. [2 ]
Cosenza, Stephen C. [2 ]
Reddy, E. Premkumar [2 ]
Reddy, M. V. Ramana [2 ]
机构：
[1] Onconova Therapeut Inc, Dept Med Chem, Newtown, PA 18940 USA
[2] Icahn Sch Med Mt Sinai, Dept Med Chem, New York, NY 10029 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2014年 / 248卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
493-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER plus breast cancer
    O'Brien, Neil A.
    Tomaso, Emmanuelle D.
    Ayala, Raul
    Tong, Luo
    Issakhanian, Shawnt
    Linnartz, Ronald
    Finn, Richard S.
    Hirawat, Samit
    Slamon, Dennis J.
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
    Aslam, Razia
    Hennessy, Bryan T.
    Toomey, Sinead
    Richards, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 167 - 167
  • [33] Palbociclib (Cyclin-Dependent Kinases CDK4 and CDK6 Selective Inhibitor) Induced Grade 3 Interstitial Pneumonitis
    Kunadharaju, R.
    Saradna, A.
    Ahmad, M.
    Fuhrer, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [34] CDK4/6 BLOCKADE IMPROVES THE EFFICACY OF PI3K INHIBITION IN BREAST CANCER
    不详
    CANCER DISCOVERY, 2014, 4 (09) : 983 - 983
  • [35] Promising Rationally Derived Combination Therapy with PI3K and CDK4/6 Inhibitors
    Muranen, Taru
    Meric-Bernstam, Funda
    Mills, Gordon B.
    CANCER CELL, 2014, 26 (01) : 7 - 9
  • [36] T-Cell Clonal Expansion and Activation Associated with Durable Clinical Response to Dual BTK and CDK4/6 Inhibitor Therapy in Mantle Cell Lymphoma
    Lee, Christina Y.
    Di Liberto, Maurizio
    Hu, Yang
    Huang, Xiangao
    Bartlett, Nancy L.
    Maddocks, Kami J.
    Leonard, John P.
    Rudqvist, Nils-Petter
    Galluzzi, Lorenzo
    Martin, Peter
    Elemento, Olivier
    Chen-Kiang, Selina
    BLOOD, 2019, 134
  • [37] Targeting the mitotic kinase NEK2 enhances CDK4/6 inhibitor efficacy by potentiating genome instability
    Bobbitt, Jessica R.
    Cuellar-Vite, Leslie
    Weber-Bonk, Kristen L.
    Yancey, Marlee R.
    Majmudar, Parth R.
    Keri, Ruth A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2025, 301 (02)
  • [38] Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
    Bonuccelli, Gloria
    Peiris-Pages, Maria
    Ozsvari, Bela
    Martinez-Outschoorn, Ubaldo E.
    Sotgia, Federica
    Lisanti, Michael P.
    ONCOTARGET, 2017, 8 (06) : 9868 - 9884
  • [39] Cell cycle and biochemical effects of PD 0183812 - a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6
    Fry, DW
    Bedford, DC
    Harvey, PH
    Fritsch, A
    Keller, PR
    Wu, ZP
    Dobrusin, E
    Leopold, WR
    Fattaey, A
    Garrett, MD
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (20) : 16617 - 16623
  • [40] Longitudinal genomic and transcriptomic analysis of mantle cell lymphoma in a targeted combination trial of a selective CDK4/6 inhibitor
    Vijay, Priyanka
    Blecua, Pedro
    Di Liberto, Maurizio
    Chiron, David
    Huang, Xiangao
    Elemento, Olivier
    Martin, Peter
    Leonard, John P.
    Mason, Christopher E.
    Chen-Kiang, Selina
    CANCER RESEARCH, 2015, 75
12345